# Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

> **NCT04703192** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 155 (actual)

## Conditions studied

- Relapsed/Refractory Peripheral T-Cell Lymphoma
- Adult T Cell Leukemia/Lymphoma

## Interventions

- **DRUG:** Valemetostat Tosylate

## Key facts

- **NCT ID:** NCT04703192
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-03
- **Primary completion:** 2023-05-10
- **Final completion:** 2027-02-19
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04703192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04703192, "Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04703192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*